| It is known that ovarian carcinoma is one of the most frequent malignant tumors in female reproductive system. Being diagnosed at late phase for the reason of no striking clinical syndrome during early stage of ovarian cancer development, most patients have a bad prognosis. The mortality of ovarian cancer is the head of gynecological malignant tumors. Even if the worldwide gynecologists have made a sustained effort in solving the difficult work, the five-year survival rate of ovarian cancer still fluctuates about25%~ 30%. Although we have exerted ourselves to elevate the survival rate with operation combined with chemotherapy and radiotherapy, the therapeutic effect is still barely satisfactory. It is urgently required that we should search an original adjuvant treatment matching with the exsiting ones to postpone their recurrence and elevate their survival rate.The intraperitoneal hyperthermic chemotherapy(IPHC) is a novel combined therapy of tumor in recent years, which can prevent the metastasis and recurrence of the malignant peritoneum carcinoma. The ovarian carcinoma is favourable to apply IPHC for the reason of its heat sensitivity, local extension and abdominal growth. Accompanying with the worldwide scholars'persistent research in vitro, animal and clinic experiments, the theory and practice of the application of IPHC in ovarian carcinoma have already being perfected. It can damage the peritoneum... |
PDF Full Text Request